Testing is available for metastatic HR+ HER2- breast cancer using our Oncopanel multigene NGS panel.
Predictive Testing
The Oncopanel assay can detect mutations in a variety of predictive genes:
- AKT1 and PTEN: Predict response to Capivasertib
- BRCA1 and BRCA2: Predict response to PARP inhibitor therapy
- ESR1: Predict response to Elacestrant
- PIK3CA: Predict response to PIK3CA inhibitors
In addition, the Oncopanel assay can detect mutations in genes associated with inherited breast cancer predisposition, in which case follow-up germline/hereditary testing is recommended (see below).
Hereditary Testing
Hereditary testing is available for patients with mutations associated with an inherited predisposition to the development of breast cancer, (see our Hereditary Cancer page for details).